Search research articles
Contact Us
Filters
Showing results (221-230 of 250) with videos related to
Page
of 25
Sort By:
Haematologica
|
November 30, 2023
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Sunil Lakhwani, Laura Rosiñol, Noemí Puig, et al.
Leukemia
|
December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Noemi Puig, Bruno Paiva, Marta Lasa, et al.
The New England Journal of Medicine
|
June 6, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
María-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Blood
|
April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Catarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
Blood
|
April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Cristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Hemasphere
|
April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
Andrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 250) with videos related to
Sort By:
Page
of 25
Haematologica
|
November 30, 2023
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Sunil Lakhwani, Laura Rosiñol, Noemí Puig, et al.
Leukemia
|
December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Noemi Puig, Bruno Paiva, Marta Lasa, et al.
The New England Journal of Medicine
|
June 6, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
María-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Blood
|
April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Catarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
Blood
|
April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Cristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Hemasphere
|
April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
Andrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Page
of 25